Medication info
Glimepiride Tablet

Glimepiride Tablet

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
Hawon Pharmaceutical Co., Ltd.
Appearance
Green rectangular tablet
Packaging
30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 200402949 · Notified 2004.06.11 · Insurance code 651500020

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adjust the dose individually for each patient. Swallow whole without chewing, with at least 1/2 cup of water. This medicine is administered orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received drug therapy, treatment should be initiated with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses greater than 4 mg provide little additional benefit, but some patients have shown better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the amount of this medicine needed may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral glucose-lowering agent to this medicine There is no precise dose equivalence between this medicine and other oral glucose-lowering agents. When switching from another oral glucose-lowering agent to this medicine, it is recommended to follow the method described under Initial dose. That is, treatment may be initiated at 1 mg daily, with dose adjustments at intervals of 1 ~ 2 weeks. The potency and duration of action of the previously administered drug should be taken into consideration. 4) Dose adjustment during treatment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia can be controlled immediately by consuming sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. This medicine is administered at a dose of 8 mg once daily with the first meal, while insulin is initiated at a low dose and increased approximately once a week according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, the addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this medicine is coadministered with metformin, and the risk may increase. Appropriate precautions should be taken.

Ingredients

Manufacturer
Hawon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood sugar control difficulties in patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to dietary and exercise therapy to enhance blood sugar control in patients with type 2 diabetes. It can also be administered as monotherapy, and when blood sugar is not sufficiently controlled, it can be used in combination with oral hypoglycemic agents or insulin. Additionally, in cases where blood sugar control is difficult with sulfonylurea or metformin monotherapy, it can be used in combination with metformin to enhance efficacy. This medication helps improve blood sugar management for patients.

How to take

Adult dose

Adjust the dose individually for each patient. Swallow whole without chewing, with at least 1/2 cup of water. This medicine is administered orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received drug therapy, treatment should be initiated with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses greater than 4 mg provide little additional benefit, but some patients have shown better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the amount of this medicine needed may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral glucose-lowering agent to this medicine There is no precise dose equivalence between this medicine and other oral glucose-lowering agents. When switching from another oral glucose-lowering agent to this medicine, it is recommended to follow the method described under Initial dose. That is, treatment may be initiated at 1 mg daily, with dose adjustments at intervals of 1 ~ 2 weeks. The potency and duration of action of the previously administered drug should be taken into consideration. 4) Dose adjustment during treatment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia can be controlled immediately by consuming sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. This medicine is administered at a dose of 8 mg once daily with the first meal, while insulin is initiated at a low dose and increased approximately once a week according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, the addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this medicine is coadministered with metformin, and the risk may increase. Appropriate precautions should be taken.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or diabetic coma. Patients who have had allergic reactions to this medication or its components, or to sulfonylureas or sulfonamides should not take this medication. It is not recommended for patients with severe liver or kidney dysfunction, and it is better to switch to insulin therapy for blood sugar control. Pregnant women or women of childbearing potential, as well as nursing mothers, should not take this medication and should switch to insulin therapy if necessary. Patients with severe infections, during and after surgery, or with severe trauma are advised to use insulin therapy and should avoid this medication. In cases of gastrointestinal disorders such as diarrhea or vomiting, proper absorption of food may be impaired, increasing the risk of hypoglycemia, so caution is needed. This medication contains lactose, so it should not be taken by patients with lactose intolerance or genetic lactose metabolic disorders. During the first week of administering this medication, the risk of hypoglycemia is high, so blood sugar should be monitored closely. Especially for elderly patients, those who have difficulty cooperating, those in poor nutritional status or skipping meals, and patients with irregular exercise and dietary patterns, the risk of hypoglycemia is elevated. Patients who consume alcohol, or have kidney or liver dysfunction may also be more sensitive to hypoglycemia, so caution is required. Additionally, those with other endocrine disorders or those who have overdosed on medications, or patients taking multiple drugs simultaneously should be attentive to the risk of hypoglycemia. Due to its blood sugar-lowering effect, this medication may cause the symptoms of hypoglycemia. Symptoms of hypoglycemia may include headache, severe hunger, nausea, fatigue, drowsiness, anxiety, confusion, vision problems, trembling, dizziness, loss of consciousness, etc. In severe cases, it can lead to seizures or coma, so if hypoglycemic symptoms occur, immediate intake of sugar or notification of healthcare professionals is necessary. During initial dosing, blurred vision, gastrointestinal symptoms, liver function abnormalities, blood abnormalities, and allergic reactions may rarely occur, so patients should be monitored closely. Allergic symptoms may include itching, rash, shortness of breath, and if these symptoms appear, immediate notification to a doctor is necessary. This medication should be taken regularly along with dietary management, exercise, and weight control to achieve optimal blood sugar control. If hypoglycemia occurs, it can be quickly treated by consuming sugar or sugar-containing beverages, so patients should always carry sugar. It is important to thoroughly educate patients and their families about the symptoms of hypoglycemia and risk factors. During treatment, regular monitoring of blood sugar and urine glucose tests should be done to check the effectiveness of the medication, and dosage adjustments or changes to treatment may be necessary as needed. Moreover, during the initial administration or when changing medications, behavioral changes due to hypoglycemia or hyperglycemia may occur, so caution is advised when driving or operating machinery. This medication may interact with other medications, so if patients are taking other drugs, they should inform their doctor or pharmacist. Certain antibiotics, antifungals, blood pressure medications, antidepressants, anticoagulants, and steroids may particularly affect blood sugar control. Drugs like beta-blockers may mask warning signs of hypoglycemic symptoms, so caution is required. Alcohol consumption may also affect the blood sugar-lowering effect of this medication, so it is recommended to avoid it. Pregnant or nursing women should not use this medication as it may pose risks to the fetus or newborn, and it is safer to consult with a doctor and switch to insulin therapy. For children under 18 years of age, the safety and efficacy of this medication have not been established, so its use is not advisable. Elderly patients may have decreased kidney function, so the dosage of this medication should be carefully adjusted, and particular attention should be paid to the risk of hypoglycemia. In cases of overdose, severe hypoglycemia may occur, so immediate hospital visit for emergency treatment is necessary. Inductions of vomiting, gastric lavage, administration of activated charcoal, etc., may be required, and intravenous glucose may be administered to rapidly restore blood sugar to normal ranges.

Side effects

  • Hypoglycemia
  • headache
  • severe hunger
  • nausea
  • vomiting
  • fatigue
  • sleep
  • sleep disturbances
  • anxiety
  • aggressiveness
Show 68 more
  • decreased concentration
  • decreased agility or motivation
  • depression
  • confusion
  • speech abnormalities
  • aphasia
  • visual impairment
  • tremors
  • incomplete paralysis
  • sensory disturbances
  • dizziness
  • weakness
  • loss of self-control
  • temporary mental confusion
  • cerebral convulsions
  • drowsiness
  • loss of consciousness
  • coma
  • shallow breathing
  • bradycardia
  • sweating
  • cold and damp skin
  • tachycardia
  • hypertension
  • palpitations
  • angina pectoris
  • venous arrhythmia
  • blurred vision
  • fullness in the upper abdomen
  • pressure sensation
  • abdominal pain
  • diarrhea
  • increased liver enzymes
  • liver dysfunction
  • bile secretion disorder
  • jaundice
  • hepatitis
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • erythrocytopenia
  • granulocytopenia
  • agranulocytosis
  • pancytopenia
  • itching
  • urticaria
  • rash
  • dyspnea
  • hypotension
  • shock
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • allergic vasculitis
  • photosensitivity reactions of the skin
  • decreased serum sodium concentration
  • taste disorders
  • hair loss
  • weight gain
  • dizziness
  • liver dysfunction
  • abdominal pain
  • arthralgia
  • dyspepsia
  • facial swelling
  • erectile dysfunction
  • facial flushing
  • gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is recommended to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature. This way, the effectiveness of the medication can be maintained for a longer period.

Appearance and packaging

Appearance

Green rectangular tablet

Package unit

30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.